Public Company News

LG Display demonstrates SDV technology leadership with ASPICE global automotive software recognition

SEOUL, South Korea, June 1, 2026 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that it has achieved Automotive SPICE (ASPICE) Capability Level 2 (CL2) from certification body C&BIS, strengthening its position as a technology-centered company as...

2026-06-02 09:00 630

Jianzhi Education Technology Announces Agreement with SeaArt AI, One of the World's Top 20 Generative AI Platforms

BEIJING, June 1, 2026 /PRNewswire/ -- Jianzhi Education Technology Group Company Limited (the "Company" or "Jianzhi") (NASDAQ: JZ), a leading EdTech company in China, today announced that it has entered into an agreement (the "Agreement") with SeaArt AI, one of the leading generative artificial ...

2026-06-01 22:00 2833

SurplusGLOBAL Secures Korean Patents for AI-Powered Export Control Automation Technology, Strengthening Safety in Semiconductor Equipment and Parts Transactions

Export Control AI Agent Applied to SemiMarket Expands Use in Transactions with Global Major Fabs SEOUL, South Korea, June 1, 2026 /PRNewswire/ -- SurplusGLOBAL (CEO: Bruce Kim) announced that it has secured Korean patents covering two core technologies implemented within its global semiconductor...

2026-06-01 21:00 2136

U Power Hydro Data Joint Venture Receives "Data Center Power & Energy Solution" Recognition at DIF Awards 2026 in Thailand

BANGKOK, June 1, 2026 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) ("U Power" or the "Company"), a provider of AI-integrated solutions for next-generation energy grids and intelligent transportation systems, building on its proprietary UOTTA™ electric vehicle ("EV") battery-swapping technology,...

2026-06-01 21:00 2053

NATURE'S MIRACLE HOLDING INC. SECURES $566,000 CONVERTIBLE PREFERRED STOCK FINANCING

ONTARIO, Calif., June 1, 2026 /PRNewswire/ -- Nature's Miracle Holding Inc. ("Nature's Miracle" or the "Company") (OTCID: NMHI), a growing agriculture technology company providing products and services to the Controlled Environment Agriculture ("CEA") industry, today announced the closing of a $...

2026-06-01 20:30 1893

Nota AI Works with NVIDIA to Expand Video AI Agent Market… Deployment of VSS-based NVA Spreads

* Enhancing field responsiveness in transportation and industrial safety through NVIDIA VSS-based video search and summarization functions * Proving the applicability of Generative AI video monitoring through cases of the Daejeon Regional Office of Construction and Management and Kolon Indust...

2026-06-01 20:00 1653

Eason Technology Announces the Formation of New Subsidiary, Four Ele Industrial Intelligent Tech to Target Power Energy, Energy Networks and New Energy Storage Facilities Scenarios

HONG KONG, June 1, 2026 /PRNewswire/ -- Eason Technology Limited ("Eason" or the "Company") (NYSE American: DXF), today announced the launch of a new wholly owned subsidiary, Four Ele Industrial Intelligent Tech. The Company plans for Four Ele Industrial Intelligent Tech to extends its digital te...

2026-06-01 18:55 2349

Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas

SILICON VALLEY, Calif. and BEIJING, June 1, 2026 /PRNewswire/ -- On May 29, 2026, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeuti...

2026-06-01 17:50 1884

China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA

BEIJING, June 1, 2026 /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, has officially received marketing approval from the U.S. Food and Drug Administration (FDA), becoming ...

2026-06-01 15:04 1827

Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types

SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer r...

2026-06-01 13:51 2499

MediaTek Collaborates with NVIDIA on the RTX Spark to Power the Next Wave of Windows PC Experiences

MediaTek brings its design expertise in CPU performance and power efficiency to the groundbreaking RTX Spark, bringing local personal agents, advanced content creation, and gaming together in small, ultra-efficient Windows PCs TAIPEI, June 1, 2026 /PRNewswire/ -- MediaTek today announced its role...

2026-06-01 13:30 2016

XPENG Announces Vehicle Delivery Results for May 2026

GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for May 2026. XPENG delivered a total of 32,158 vehicles in May, representing a 4% increas...

2026-06-01 12:47 2324

Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi")today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's b...

2026-06-01 11:09 2400

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...

2026-06-01 08:15 1834

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...

2026-06-01 08:15 2209

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...

2026-06-01 08:00 1409

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...

2026-06-01 08:00 1937

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...

2026-05-31 21:00 1800

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...

2026-05-31 08:09 2919

CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements

HONG KONG, May 29, 2026 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS) today announced that it received a notification letter (the "Notification Letter") from Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2026, indicating th...

2026-05-30 08:16 2722
12345 ... 766